Table 1 Baseline demographic and clinical characteristics of study population
BSG failure from database (n = 12 patients) | BSG failure cohort single center (n = 6 patients) | Control cohort single center (n = 25 patients) | p (CI of difference)* | |
|---|---|---|---|---|
Mean age, y | 67.25 (± 9.22) | 61.73 (± 8.39) | 71.84 (± 9.4) | 0.022 (1.5; 18.7) |
Male sex | 10 (83.3%) | 5 (83.3%) | 15 (60%) | 0.383 |
Comorbidities | ||||
Hypertension | 11 (91.7%) | 5 (83.3%) | 24 (96%) | 0.355 |
Hyperlipidemia | 10 (83.3%) | 6 (100%) | 20 (80%) | 0.553 |
Diabetes mellitus II | 3 (25%) | 2 (33.3%) | 7 (28%) | 1.000 |
Smoking | 4 (33.3%) | 2 (33.3%) | 9 (36%) | 1.000 |
COPD | 4 (33.3%) | 2 (33.3%) | 8 (32%) | 1.000 |
CKD | 5 (41.7%) | 3 (50%) | 7 (28%) | 0.358 |
Atrial fibrillation | 0 (0%) | 0 (0%) | 5 (20%) | 0.553 |
Heart failure | 1 (8.3%) | 0 (0%) | 2 (8%) | 1.000 |
Cancer | 1 (8.3%) | 1 (16.7%) | 5 (20%) | 1.000 |
Arterial disease | ||||
Coronary | 5 (41.7%) | 3 (50%) | 10 (40%) | 0.676 |
Peripheral | 1 (8.3%) | 0 (0%) | 6 (24%) | 0.309 |
Central | 0 (0%) | 0 (0%) | 6 (24%) | 0.309 |
Aortic surgery/intervention priorly | 5 (41.7%) | 3 (50%) | 10 (40%) | 1.000 |
Indication | ||||
TAAA, Crawford: | 0.391 | |||
I | 1 (8.3%) | 1 (16.7%) | 2 (8%) | |
II | 4 (33.3%) | 2 (33.3%) | 6 (24%) | |
III | 0 (0%) | 0 (0%) | 0 (0%) | |
IV | 5 (41.7%) | 3 (50%) | 15 (60%) | |
V | 2 (16.7%) | 0 (0%) | 2 (8%) | |
Mean aneurysm Ø, mm | 71.00 (± 0.79) | 72.33 (± 4.15) | 66.12 (± 2.3) | 0.247 |
Urgency | 0.654 | |||
Acute | 0 (0%) | 0 (0%) | 1 (4%) | |
Urgent | 2 (16.7%) | 2 (33.3%) | 4 (16%) | |
Elective | 10 (83.3%) | 4 (66.7%) | 20 (80%) | |
Index procedure | ||||
Main body | 1.000 | |||
Jotec | 11 (91.7%) | 5 (83.3%) | 20 (80%) | |
Cook | 1 (8.3%) | 1 (16.7%) | 5 (20%) | |
Total br, n | 44 | 23 | 85 | |
Mean br/pt | 3.67 (± 0.65) | 3.83 (± 0.41) | 3.4 (± 0.96) | 0.391 |
Successful br, n | 44 | 23 | 84 | |
Successful br/pt | 3.67 (± 0.65) | 3.83 (± 0.41) | 3.36 (± 0.95) | 0.314 |
Religning, n | 17 | 17 | 58 | |
Religning/pt | 1.42 (± 1.78) | 2.83 (± 1.47) | 2.32 (± 1.52) | 0.542 |
Extensions, n | 18 | 11 | 35 | |
Extensions/pt | 1.50 (± 1.17) | 1.83 (± 1.17) | 1.40 (± 1.63) | 0.339 |
TAM, n | 35 | 28 | 93 | |
TAM/pt | 2.92 (± 2.47) | 4.67 (± 2.16) | 3.72 (± 2.30) | 0.368 (− 3.1; 1.2) |
Technical success of BSG | 0.330 | |||
Primary | 10 (83.3%) | 4 (66.7%) | 22 (88%) | |
Assisted | 2 (16.7%) | 2 (33.3%) | 2 (8%) | |
Reintervention 30 days | 3 (25%) | 2 (33.3%) | 7 (28%) | 1.000 |
Aortic reintervention (prior to BSG failure) | 7 (58.3%) | 6 (100%) | 9 (36%) | 0.007 |
FU CT/Angiography, months | 41.69 (± 26.06) | 58.43 (± 26.54) | 19.89 (± 34.43) | 0.009 |
FU clinically, months | 41.71 (± 26.07) | 58.47 (± 26.55) | 21.80 (± 34.30) | 0.012 |
BSG related mortality | 2 (16.7%) | 2 (33.3%) | 0 (0%) | 0.032 |